RxDoctor Payments Data

Shaoqing Zhou, MD

Urology · Annapolis, MDNPI 1003108549

Payments from drug & device makers

What this record shows

This record is dominated by education: $12,000 of the $15,450 with a category attached, or 77.7%. Intuitive Surgical accounts for 86.4% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2023 at $13,621 and has fallen 95.1% since, to $667 in 2025.

$15,450in general payments, 2019–2025

Across 74 payments — averaging $208.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$13K
  • Dendreon Pharmaceuticals LLC$251
  • Sumitomo Pharma America, Inc.$249
  • Urogen Pharma, Inc.$174
  • Pfizer$152
  • Axonics, Inc.$124
  • plus $1K from 29 others

What the payments were for

  • Travel & lodging$4473%
  • Food & beverage$3,00219%
  • Education$12,00078%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,450 in reported general payments places this provider in the 85th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$604,788
Medicare patients
1,286
Services billed
10,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix40$116,620
GemtesaVibegron32$42,512
Testosterone15$5,957
Tamsulosin Hcl263$4,735
Finasteride29$1,043
NitrofurantoinNitrofurantoin Macrocrystal18$606
Oxybutynin Chloride ErOxybutynin Chloride19$476
CefuroximeCefuroxime Axetil50$199
Levofloxacin26$81
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen26$63
Ciprofloxacin Hcl30$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$249$159,13372 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 274 urology providers in Maryland.

Other urology in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →